Absci Corporation Common Stock Q2 2025 Earnings Recap

ABSI Q2 2025 August 13, 2025

Get alerts when ABSI reports next quarter

Absci's Q2 2025 results reflect significant advancements in its clinical pipeline, including the initiation of Phase I trials for ABS-101 and promising preclinical data for ABS-201, bolstered by a strengthened balance sheet through recent funding.

Earnings Per Share Miss

$-0.24 vs $-0.19 est.

-26.3% surprise

Revenue Miss

593000 vs 5174500 est.

-88.5% surprise

Market Reaction

1-Day -6.35%

5-Day -16.03%

30-Day -21.15%

See ABSI alongside your other holdings

Add to your portfolio — free

Key Takeaways

Initiated Phase I clinical trials for ABS-101, a key anti-TL1A antibody, with interim results expected later this year.
Progressing towards a Phase I/IIa trial for ABS-201, targeting androgenetic alopecia, anticipated to start in early 2026.
Successfully raised approximately $64 million in gross proceeds to enhance the balance sheet and support ongoing projects.
Ongoing discussions with multiple partners for potential drug creation collaborations, including a large pharmaceutical company.
Continued development of innovative antibody programs and AI-driven drug creation platform, demonstrating strong interest from prospective partners.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit ABSI on AllInvestView.

Next Q3 2025